SYK and Alzheimer disease: Nilvadipine has the capacity to be of benefit during multimodal Alzheimer’s Disease (AD) treatment by its effects mediated by the unique target of Syk; and a Phase III clinical trial of Nilvadipine in AD has newly been fruitfully wrapped up in Europe [265] (ClinicalTrials.gov: NCT02017340).